Atrogi
CompanySwedenFounded 2013
Atrogi develops one asset, in phase 1 (ATR-258 in obesity). Mostly small molecule acting on lipid and ceramide metabolism, ADRB2 and GRK2; based in Sweden, founded in 2013.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 0
- Signals
Pipeline
1Oral GRK2-biased beta-2 adrenergic receptor modulator designed to reduce fat while improving muscle function.
Phase 1, Small molecule, Lipid and ceramide metabolism, ADRB2, obesity
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Similar companies6